In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.74 in the last session, up 1.63% from day before closing price of $3.68. In other words, the price has increased by $1.63 from its previous closing price. On the day, 3.09 million shares were traded. AKBA stock price reached its highest trading level at $3.755 during the session, while it also had its lowest trading level at $3.61.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 09 ’25 when Malabre Richard C sold 15,000 shares for $4.01 per share. The transaction valued at 60,150 led to the insider holds 266,914 shares of the business.
Malabre Richard C sold 13,334 shares of AKBA for $47,069 on Jun 04 ’25. The SVP, Chief Accounting Officer now owns 266,914 shares after completing the transaction at $3.53 per share. On Mar 03 ’25, another insider, Butler John P., who serves as the CEO and President of the company, sold 46,409 shares for $1.83 each. As a result, the insider received 84,928 and left with 2,557,921 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 982258624 and an Enterprise Value of 1064480000. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.31 while its Price-to-Book (P/B) ratio in mrq is 39.81. Its current Enterprise Value per Revenue stands at 5.757 whereas that against EBITDA is 104.34.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.87, which has changed by 2.6666667 over the last 52 weeks, in comparison to a change of 0.12463009 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $0.80. The 50-Day Moving Average of the stock is 28.61%, while the 200-Day Moving Average is calculated to be 78.64%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 4.98M shares per day over the past 3-months and 4850090 shares per day over the past 10 days. A total of 261.64M shares are outstanding, with a floating share count of 251.57M. Insiders hold about 4.21% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AKBA as of 1749772800 were 18498837 with a Short Ratio of 3.72, compared to 1747267200 on 19722763. Therefore, it implies a Short% of Shares Outstanding of 18498837 and a Short% of Float of 7.12.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
